Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
ObjectivesTo compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying antirheumatic drugs (bDMARDs).MethodsPatients fro...
Main Authors: | Sofia Ramiro, Alexandre Sepriano, Jose Marona, Santiago Rodrigues-Manica, Fernando Pimentel-Santos, Ana Filipa Mourão, Nélia Gouveia, Jaime Cunha Branco, Filipe Vinagre, João Tavares-Costa, João Rovisco, Miguel Bernardes, Nathalie Madeira, Rita Cruz-Machado, Raquel Roque, Joana Leite Silva, Mary Lucy Marques, Raquel Miriam Ferreira |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-05-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/6/1/e001145.full |
Similar Items
-
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
by: Santiago Rodrigues Manica, et al.
Published: (2020-08-01) -
Intra-rater reliability of the bath ankylosing spondylitis disease activity index (BASDAI) and the bath ankylosing spondylitis functional index (BASFI) in children with spondyloarthritis
by: Batthish Michelle, et al.
Published: (2012-07-01) -
Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference
by: Sofia Ramiro, et al.
Published: (2021-08-01) -
The European Portuguese version of the ASAS Health Index for Patients with Spondyloarthritis: Measurement properties
by: Santiago Rodrigues-Manica, et al.
Published: (2020-01-01) -
HLA Allele Prevalence in Disease-Modifying Antirheumatic Drugs-Responsive Enthesitis and/or Arthritis Not Fulfilling ASAS Criteria: Comparison with Psoriatic and Undifferentiated Spondyloarthritis
by: Elvira Favoino, et al.
Published: (2021-07-01)